Search for Clinical Trial Results
Carcinoid Syndrome - 50 Studies Found
Status | Study |
Completed |
Study Name: Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy Condition: Carcinoid Syndrome Date: 2009-02-25 Interventions:
|
Completed |
Study Name: A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea Condition:
Date: 2010-10-20 |
Completed |
Study Name: An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males Condition: Carcinoid Syndrome Date: 2013-08-27 Interventions: Drug: 500 mg [14C]-LX1606 500 mg dose of LX1606 containing a target dose of 3.32 Megabecquerel (MBq) of |
Terminated |
Study Name: P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome Condition: Neuroendocrine Carcinoma Date: 2013-06-21 Interventions: Drug: Octreotide LAR Octreotide LAR as outlined in Treatment Arm. |
Completed |
Study Name: Azilect + Antidepressant Chart Review Condition: Serotonin Syndrome Date: 2009-08-06 Interventions:
|
Completed |
Study Name: Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor Condition:
Date: 2006-12-13 Interventions:
|
Completed |
Study Name: Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors Condition:
Date: 1999-11-01 Interventions:
|
Completed |
Study Name: Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors Condition: Carcinoid Tumors Date: 2004-07-30 Interventions: Drug: Pasireotide (SOM230) Open label. Patients received starting dose of 300 µg of study drug subc |
Withdrawn |
Study Name: Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Condition:
Date: 2005-09-26 Interventions:
|
Active, not recruiting |
Study Name: Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Condition:
|